Reproductive Medical Center, Peking University Third Hospital, Beijing, China.
Gynecol Endocrinol. 2012 Oct;28(10):800-4. doi: 10.3109/09513590.2012.665103. Epub 2012 Mar 20.
Gonadotropin-releasing hormone (GnRH) antagonists for controlled ovarian stimulation (COS) were only recently introduced into China. The efficacy and safety of the GnRH antagonist ganirelix was assessed in a multicenter, controlled, open-label study, in which Chinese women were randomized to either ganirelix (n = 113) or a long GnRH agonist protocol of triptorelin (n = 120). The primary end point was the amount of recombinant follicle-stimulating hormone (rFSH) required to meet the human chorionic gonadotropin criterion (three follicles ≥17 mm). The amount of rFSH needed was significantly lower for ganirelix (1272 IU) vs. triptorelin (1416 IU; P< 0.001). Ongoing pregnancy rates per started cycle were 39.8% (ganirelix) and 39.2% (triptorelin). Although both treatments were well tolerated, cancellation due to risk of ovarian hyperstimulation syndrome (OHSS) was less frequent with ganirelix (1.8%) than triptorelin (7.5%) (P = 0.06). Less rFSH was needed in the ganirelix protocol than the long GnRH agonist protocol, with fewer reported cases of OHSS and similar pregnancy rates.
促性腺激素释放激素（GnRH）拮抗剂最近才被引入中国，用于控制性卵巢刺激（COS）。在中国进行的一项多中心、对照、开放性研究中评估了 GnRH 拮抗剂加尼瑞克的疗效和安全性，将中国女性随机分为加尼瑞克组（n = 113）或长效 GnRH 激动剂曲普瑞林组（n = 120）。主要终点是达到人绒毛膜促性腺激素标准（≥17mm 的三个卵泡）所需的重组卵泡刺激素（rFSH）量。加尼瑞克（1272IU）所需的 rFSH 量明显低于曲普瑞林（1416IU；P<0.001）。每个启动周期的持续妊娠率分别为 39.8%（加尼瑞克）和 39.2%（曲普瑞林）。虽然两种治疗方法均耐受良好，但加尼瑞克（1.8%）的卵巢过度刺激综合征（OHSS）风险导致取消治疗的频率低于曲普瑞林（7.5%）（P = 0.06）。加尼瑞克方案所需的 rFSH 少于长效 GnRH 激动剂方案，OHSS 的报告病例较少，妊娠率相似。
